# Michael S. Oh

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michael-s-oh/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,392 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 20 |
| i10-index | 27 |
| Last Known Institution | APLA Health |
| OpenAlex ID | https://openalex.org/A5043526350 |
| ORCID iD | 0000-0002-7206-771X |
| Works | 88 |

## Researcher papers

- [The leukodystrophy protein FAM126A (hyccin) regulates PtdIns(4)P synthesis at the plasma membrane](https://scholariq.org/papers/the-leukodystrophy-protein-fam126a-hyccin-regulates-ptdins-4-p-synthesis-at-the/)
- [Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions](https://scholariq.org/papers/detection-of-minimal-residual-disease-using-ctdna-in-lung-cancer-current/)
- [Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity](https://scholariq.org/papers/cholesterol-tethered-platinum-ii-based-supramolecular-nanoparticle-increases/)
- [CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer](https://scholariq.org/papers/cxcl9-10-engineered-dendritic-cells-promote-t-cell-activation-and-enhance-immune/)
- [Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating <i>RET</i> Alterations and Oncogenic Signaling Pathway Aberrations](https://scholariq.org/papers/analysis-of-cell-free-dna-from-32-989-advanced-cancers-reveals-novel-co/)
- [Architecture of the human PI4KIIIα lipid kinase complex](https://scholariq.org/papers/architecture-of-the-human-pi4kiii-lipid-kinase-complex/)
- [Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma](https://scholariq.org/papers/mutations-in-dna-repair-genes-are-associated-with-increased-neoantigen-burden/)
- [The Impact of Beta Blockers on Survival Outcomes in Patients With Non–small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors](https://scholariq.org/papers/the-impact-of-beta-blockers-on-survival-outcomes-in-patients-with-non-small-cell/)
- [Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer](https://scholariq.org/papers/clinical-and-immunological-implications-of-frameshift-mutations-in-lung-cancer/)
- [Combined PI3Kα-mTOR Targeting of Glioma Stem Cells](https://scholariq.org/papers/combined-pi3k-mtor-targeting-of-glioma-stem-cells/)
- [Brief Report: The Genomic Landscape of Small Cell Lung Cancer in Never-Smoking Patients](https://scholariq.org/papers/brief-report-the-genomic-landscape-of-small-cell-lung-cancer-in-never-smoking/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [vaccines and immunoinformatics approaches](https://scholariq.org/topics/vaccines-and-immunoinformatics-approaches/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Researcher university

- [APLA Health](https://scholariq.org/institutions/apla-health/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.